Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience – IL PSO (Italian Landscape Psoriasis)

In this multicentre real-life study, bimekizumab showed exploratory evidence of the cumulative clinical benefit of biologics in moderate-to-severe psoriasis. These findings highlight the importance of cumulative endpoints and individualized treatment strategies in daily practice.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Dermatology
Published
2025-10-31
DOI
https://doi.org/10.1093/ced/llaf486
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience – IL PSO (Italian Landscape Psoriasis)

Giovanni Pellacani, Diego Orsini, Luca Mastorino, Martina Maurelli et al.
Clinical and Experimental Dermatology
Psoriasis: Treatment and Pathogenesis
article

Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience – IL PSO (Italian Landscape Psoriasis)

Giovanni Pellacani, Diego Orsini, Luca Mastorino, Martina Maurelli, Angelo Valerio Marzano, Simone Ribero, Francesco Loconsole, Annunziata Dattola, Luigi Gargiulo, Eugenia Veronica Di Brizzi, Matteo Megna, Giampiero Girolomoni, Claudio Guarneri, Emanuele Trovato, Emanuele Cozzani, Claudia Lasagni, Massimo Travaglini, Piergiorgio Malagoli, Anna Campanati, Paolo Dapavo, Chiara Assorgi, Valentina Dini, Antonio Costanzo, Luca Potestio, Martina Burlando, Alessandra Michelucci, Luciano Ibba, Andrea Carugno, Nicola Zerbinati, Alessandra Narcisi, Francesca Maria Gaiani, Antonio Di Tano, Francesco Messina, Anna Balato, Maria Concetta Fargnoli, Carlo Giovanni Carrera
article en

Abstract

In this multicentre real-life study, bimekizumab showed exploratory evidence of the cumulative clinical benefit of biologics in moderate-to-severe psoriasis. These findings highlight the importance of cumulative endpoints and individualized treatment strategies in daily practice.

Clinical and Experimental DermatologyVol. 51(3)
University of Siena (IT), University of Messina (IT), University of Insubria (IT), University of Verona (IT), University of Modena and Reggio Emilia (IT), Marche Polytechnic University (IT), Humanitas University (IT), Scuola Superiore Sant'Anna (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Santa Chiara (IT), IRCCS Policlinico San Donato (IT), Ospedale A. Perrino (IT), San Gallicano Hospital (IT), Ospedale Policlinico San Martino (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), IRCCS Humanitas Research Hospital (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 67%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.